Navigation Links
Viron granted U.S. Patents for Organ Transplant and Arthritis Drug Candidates
Date:12/22/2009

LONDON, ON, Dec. 22 /PRNewswire/ - Viron Therapeutics Inc., a biotechnology company pioneering the development of virally-derived protein therapeutics, today announced that it has been granted U.S. patents related to three of its drug candidates, VT-111, VT-346 and VT-384. These patents join a portfolio of more than 80 previously-granted patents for Viron's multiple therapeutic candidates. Viron's unique drug discovery platform identifies proteins expressed by non-human viruses that have evolved over millions of years of evolutionary selection to evade their host's immune system, endowing them with powerful immuno-modulatory and anti-inflammatory properties.

The new patent, US 7,514,405, entitled "Methods for treating transplant rejection," covers the treatment of chronic transplant rejection by administering VT-111 in combination with an immunosuppressant, such as cyclosporine. "This patent extends protection for VT-111 in transplant out to at least 2021," said Kevin Sullivan, Vice President of Business Development for Viron Therapeutics. "This provides ample time for us to unlock the commercial potential arising from upcoming organ transplant trials." Viron will pursue the transplant indication in parallel with Acute Coronary Syndromes (ACS) for VT-111, due to the significant unmet medical need in this space and the resulting rapid regulatory path forward. There are currently no therapeutic molecules targeting chronic organ rejection.

Viron's lead therapeutic candidate, VT-111, has demonstrated potent effects in preclinical suppression of chronic organ transplant rejection and, in a Phase IIa clinical trial of 48 patients, demonstrated reduced cardiac tissue damage in patients with ACS receiving cardiac stent implants. "It is remarkable to see such a small trial demonstrate such a strong, statistically significant impact in this target population," said Mr. Sullivan. "These trial results provide a compelling validation of Viron
'/>"/>

SOURCE Viron Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies
2. Landfill mining reduces environmental impact of growing waste
3. Landfill mining reduces environmental impact of growing waste
4. Nanowire generates power by harvesting energy from the environment
5. Caliper Life Sciences Awarded National Institute of Environmental Health Services Contract Valued to $7.0 Million
6. Environmental Tectonics Corporations BioMedical Division Announces New Contract
7. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
8. Environmental Tectonics Corporation Announces Sale of Monoplace Hyperbaric Chambers
9. NanoLogixs Hydrogen-From-Waste Technology at Welchs Foods Featured on Environmental Radio Program
10. Nanotechs health, environmental impacts worry scientists and the public
11. Fixed C-Arms Revolutionize Operating Room Environments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Freeslate, Inc ., ... announced that Lupin Limited, one of India’s top five ... Protégé PharmD System for high throughput solid form ... focused on a wide range of quality, affordable generic ...
(Date:1/14/2014)... 2014 Carahsoft and CDS Federal Services ... 2014 at 2pm EST (11am PST), “Natural Language Processing: ... on how technology can turn raw, heterogeneous data into ... agencies. The online webinar will last approximately one hour. ...
(Date:1/14/2014)... 2014 EquitiesIQ, a leading informational research ... Alliqua is an emerging biomedical company acquiring, developing, manufacturing, ... market. , Free report download: http://equitiesiq.com/reports/alliqua/ , ... management team and Board, which launched the company’s new ...
(Date:1/14/2014)... In recent years, growing suspicion about the pharmaceutical ... and promotion has led to unprecedented levels of public ... about the insidious impact of commercialization of research, has ... the world’s biggest pharmas for illegal marketing activities, allegations ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... Inc. and Asahi Kasei,Medical Co., Ltd., who have ... use with Planova(TM) virus removal filters,have reached agreement ... Kasei Medical,s full ownership. The integration of,operations will ... TechniKrom, Inc., a,wholly owned subsidiary of Asahi Kasei ...
... Inc., a biotechnology company delivering breakthrough therapies in ... is a SILVER level sponsor of the 2009 ... conference, put on by the Alzheimer,s Association, is ... 2009 will take place July 11-16 in Vienna, ...
... 17 The Pittsburgh Life Sciences Greenhouse (PLSG), ... in western Pennsylvania, has surpassed the $13 million ... in direct investments in nearly 60 companies has ... the region. The PLSG continues to propel the ...
Cached Biology Technology:TechniKrom's Biopharmaceutical Equipment Operations to be Integrated With Asahi Kasei Medical 2Accera, Inc. Sponsors Alzheimer's Association's 2009 ICAD Conference 2The Pittsburgh Life Sciences Greenhouse Starts 2009 With Investment Momentum 2The Pittsburgh Life Sciences Greenhouse Starts 2009 With Investment Momentum 3The Pittsburgh Life Sciences Greenhouse Starts 2009 With Investment Momentum 4The Pittsburgh Life Sciences Greenhouse Starts 2009 With Investment Momentum 5
(Date:4/24/2014)... common plant puts out a welcome mat to bacteria seeking ... , The study published this week in the Proceedings ... during the battle between microbe and host that researchers can ... humble and oft-studied plant Arabidopsis puts out a ... as if a hostile army were unknowingly passing by a ...
(Date:4/23/2014)... This news release is available in French and ... woman? Male or female? In humans and other mammals, the difference ... Y chromosome. It is present only in males, where the two ... chromosomes. Thus, the Y is ultimately responsible for all the morphological ... not always been the case. A very long time ago, the ...
(Date:4/23/2014)... male black widow spiders prefer their female mates to ... preference by male spiders. , The study, ... a professor in UTSC,s Department of Biological Sciences, found ... males overwhelmingly chose to mate with well-fed, unmated females. ... a potential mate is well-fed and unmated by pheromones ...
Breaking Biology News(10 mins):How a plant beckons the bacteria that will do it harm 2How a plant beckons the bacteria that will do it harm 3Male or female? 2Male or female? 3Picky male black widow spiders prefer well-fed virgins 2
... and, new research shows, an infrared laser can make a ... and Vanderbilt University found that pulsed light can pace contractions ... the tissue. The work, "Optical pacing of the embryonic heart," ... Nature Photonics on Aug. 15, 2010. According to ...
... 27 BIO-key International, Inc. (OTC Bulletin Board: http://photos.prnewswire.com/prnh/20050509/BIOKEYLOGO ) ... What: , BIO-key International, Inc. Second Quarter ... Thursday, July 29, 2010 - 10:00 a.m. Eastern Time ... Live via phone by dialing 800-860-2442 and asking for the BIO-key call ...
... 13, 2010The easy accessibility of the eye and the ... offer hope for using gene therapy to provide long-term ... Human Gene Therapy, a peer-reviewed journal published by Mary ... replacement of a human gene to preserve photoreceptor function ...
Cached Biology News:A heart beats to a different drummer 2BIO-key® Announces Second Quarter 2010 Earnings Release and Conference Call Schedule 2BIO-key® Announces Second Quarter 2010 Earnings Release and Conference Call Schedule 3Promising results of gene therapy to treat diseases of the eye 2
... Situ Assay Kit is a fluorescent-based assay ... undergoing apoptosis. The kit is for research ... or therapeutic procedures. CHEMICON®s CaspaTag™ Pan-Caspase In ... to detect active caspases. The methodology is ...
... is a fluorescein-conjugated jetSI-ENDO ... at 520 nm), the powerful ... are used to determine the ... intracellular delivery and trafficking of ...
... Cellular uptake of long double stranded ... RNA interference in a diverse group of ... culture. RNA interference leads to the inhibition ... destruction of the target messenger RNA (mRNA). ...
... and reduced space requirements of the ... DNA analysis technology affordable .The benchtop ... of SEQUENOM's applications and assays, including: ... , Gene Expression Analysis (QGE) , ...
Biology Products: